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Abstract
Introduction: Despite the existence of guidelines, painful neuropathy is often inap-
propriately treated. We sought to determine the effectiveness of a clinical decision
support system on guideline-recommended medication use.
Methods: We randomized neurology providers, stratified by subspecialty, to a best
practice alert (BPA) linked to a Smartset or a BPA alone when seeing patients with
neuropathy. The primary outcome was the proportion of patients with uncontrolled
nerve pain prescribed a guideline-recommended medication. Generalized estimating
equations were used to assess effectiveness.
Results: Seventy-five neurology providers (intervention 38, control 37) treated 2697
patients with neuropathy (intervention 1026, control 671). Providers did not
acknowledge the BPA in 1928 (71.5%) visits. Only four of eight intervention arm
neurologists who treated patients with uncontrolled nerve pain opened the Smartset.
The intervention was not associated with guideline-recommended medication use
(odds ratio 0.52, 0.18-1.48; intervention 52%, control 54.8%).
Discussion: Our intervention did not improve prescribing practices for painful neu-
ropathy. Physicians typically ignored the BPAs/Smartset; therefore, future studies
should mandate their use or employ alternate strategies.
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1 | INTRODUCTION
Neuropathy is a highly prevalent and painful condition.1-3 Recent
reports indicate that tricyclic antidepressant drugs, serotonin norepi-
nephrine update inhibitors, and gabapentinoids are efficacious for the
treatment of neuropathic pain.4-7 Despite this robust evidence, we pre-
viously demonstrated that patients with neuropathy rarely receive
more than one guideline-recommended medication.8 Furthermore,
almost two-thirds of patients with neuropathy receive at least one
opioid prescription, and nearly 9% receive chronic opioid therapy, often
prior to any guideline-recommended medications.8 Because opioid
treatment is associated with worse functional outcomes in patients
with neuropathy, an intervention designed to increase guideline-
recommended medication use and decrease opioid use is essential.9
Clinical decision support systems (CDSS) could improve the use
of guideline-recommended neuropathic pain medications while
decreasing opioid use. Meta-analyses have demonstrated that CDSS
interventions can improve physician behavior in diverse healthcare
Abbreviations: BPA, best practice alert; CDSS, clinical decision support system; GEE, generalized estimating equation; RCT, randomized, controlled trial.
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processes.10-13 We developed a CDSS that uses a best practice alert
(BPA) linked to a Smartset (Epic, Verona, Wisconsin) to facilitate the
ordering of guideline-recommended neuropathic pain medications
and recommends against opioid treatment. We tested the effective-
ness of the CDSS through a randomized, controlled trial (RCT).
2 | MATERIALS AND METHODS
2.1 | Simulation study and power calculation
Prior to study implementation, we performed simulations to deter-
mine the appropriate sample size. We used 3 months of preliminary
data from neurologists at the University of Michigan to estimate the
frequency of patients with uncontrolled neuropathic pain, proportion
of patients treated with guideline-recommended medications, and the
typical number of patients treated per provider. We estimated 80.1%
power to detect a 5% increase in guideline-recommended prescrip-
tions for 1000 patients over 1 year using a generalized estimating
equations (GEE) model with exchangeable correlation structure.
2.2 | Intervention
Neurologists at the University of Michigan were provided study
information through a presentation at a mandatory faculty meeting
and several subsequent emails. Each provider was given an opportu-
nity not to participate, but all chose to participate. The 103 neurolo-
gists were assigned to receive the BPA with or without the Smartset
using block randomization, stratified by provider subspecialty (gen-
eral neurologists n = 7, neuromuscular specialists n = 4, neurologists
with specialties other than neuromuscular n = 46, neurology fellows
n = 19, neurology residents n = 17, and neurology nurse practitioners
n = 10). Patients with neuropathy were identified by using ICD-10
codes (G60-G65, E08-11.40/42, E13.40/42, M79.2, A36.83,
B27.01/11/81/91, B26.84, B02.23, M34.83) or when “peripheral
neuropathy” was included as the chief complaint or in the problem
summary list. When a patient with neuropathy met inclusion criteria,
the BPA was automatically triggered with (intervention group) or
without (control group) the Smartset. Figure S1A,B displays images
of the BPA and Smartset, respectively. Providers received the BPA
and then determined nerve pain status and entered medication sta-
tus as follows (Figure S1A):
1. No nerve pain
2. Well controlled nerve pain, off medication
3. Well controlled nerve pain, on medication
4. Uncontrolled nerve pain
When the patient had uncontrolled nerve pain, the intervention group
would receive a link to the Smartset, which gave information involving
guideline-recommended medications including dosage information, typical
medication pricing, advice to avoid opioid medication use, and a link to the
American Academy of Neurology guidelines (Figure S1B).5 Both the BPA
and the Smartset were delivered through the electronic medical record
used at the University of Michigan (Epic, Verona, Wisconsin).
2.3 | Outcomes
The primary outcome was the proportion of patients with uncon-
trolled nerve pain that were prescribed a guideline-recommended
medication. The secondary outcome was the proportion of patients
with uncontrolled nerve pain that were prescribed an opioid. To
understand the use of our CDSS, we collected two process out-
comes, the proportion of BPAs acknowledged and the proportion of
Smartsets opened.
2.4 | Statistical analysis
Descriptive statistics were used to characterize patients with uncon-
trolled nerve pain. We report the frequencies that guideline-
recommended medications, opioids, or other potential neuropathic
pain medications were prescribed. The primary analysis used GEE
with a logit link to assess the effects of the intervention on guideline-
recommended prescriptions. In addition to adjusting for patient fac-
tors (age, sex, race, insurance plan type) and provider subspecialty, the
GEE approach accounts for clustering at the neurologist level because
the same provider may treat multiple patients. Data analysis was com-
pleted in Rv.3.4.2 (R Foundation for Statistical Computing, Austria,
Vienna). This study was approved by the University of Michigan Insti-
tutional Review Board (HUM00109137).
3 | RESULTS
Between July 14, 2016 and July 13, 2017, 75 neurology providers
(intervention 38 [50.7%], control 37 [49.3%]) treated 2697 patients
with neuropathy (intervention 1026 [38%], control 1671 [62%]).
Providers did not acknowledge the BPA in 1928 (71.5%) visits
(intervention 789 [77.3%], control 1139 [68%]). When the BPA
was acknowledged, 6.9% of patients had controlled nerve pain
without medication (intervention 14 [5.4%], control 39 [6.7%]),
27.2% of patients had controlled nerve pain with medication (inter-
vention 7 [30.2%], control 131 [22.4%]), 37.6% of patients had no
nerve pain (intervention 99 [38.5%], control 190 [32.5%]), and
28.4% of patients had uncontrolled nerve pain (intervention
41 [15.9%], control 177 [30.3%]). There were eight neurologists in
the intervention arm and 20 in the control arm that treated
patients with uncontrolled nerve pain. Only four of eight neurolo-
gists in the intervention arm (25/41 patients) opened the Smartset
during follow-up.
Demographic, health plan, and provider subspecialty for patients
with uncontrolled nerve pain is presented in Table 1. Despite stratifying
by provider subspecialty, we observed different patterns among
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providers who treated patients with uncontrolled nerve pain. Patients in
the intervention arm were treated by residents and attending neurolo-
gists. Patients in the control arm were treated by general neurologists,
neuromuscular specialists, residents, fellows, and attending neurologists.
Frequencies of relevant medications that were prescribed to
patients are presented in Table 2. The proportion of patients receiving
guideline-recommended medications was similar in the intervention
and control arms. No patients were prescribed an opioid in the inter-
vention arm compared with 11 patients in the control arm.
The GEE revealed that the intervention was not associated with
guideline-recommended medication use (crude odds ratio [OR] 0.89,
0.36-2.24; adjusted OR 0.52, 0.18-1.48). Men (adjusted OR 2.10,
1.14-3.89) and patients treated by residents (adjusted OR 2.18,
1.12-5.66, reference = general neurologists) had an increased odds
of guideline-recommended medication use. Insurance type, patient
race, and age were not significantly associated with guideline-
recommended medication use. We were unable to fit a GEE model
for the secondary outcome because there were no opioids pre-
scribed in the intervention arm.
4 | DISCUSSION
Our intervention failed to improve either the primary or secondary out-
come measures. Future interventions should be informed by the les-
sons learned from our negative trial. Our CDSS failed in two major
capacities. First, our process outcomes indicated that physicians usually
did not acknowledge the BPA or use the Smartset intervention. The
low use rate resulted in an insufficient sample size to assess the effec-
tiveness of the intervention. Our observed low use is not unusual; a
previous meta-analysis found that most RCTs (8/12) observed poor
physician use of CDSS interventions (however, this information was
rarely reported).11 One solution involves implementing a mandatory
BPA with an automatically fired Smartset. A mandatory-response BPA
would improve CDSS use; however, previous researchers found no dif-
ference in the rate by which physicians accepted the CDSS




patients, n = 25
Control
patients, n = 177
Age, mean ± SD, y 58.3 ± 15.2 56.6 ± 13.9
Men, n (%) 17 (68) 73 (41.2)
Race
White 23 (92) 158 (89.3)
Black 2 (8) 15 (8.5)
Asian 0 (0) 2 (1.1)
Other 0 (0) 2 (1.1)
Ethnicity Hispanic, n
(%)
0 (0) 6 (3.4)
Health plan, n (%)
Medicare 9 (36) 55 (31.1)
Blue Cross Blue
Shield
8 (32) 54 (30.5)
Blue Care Network 2 (8) 20 (11.3)
Priority Health 1 (4) 13 (7.3)
Meridian Health
Plan
3 (12) 8 (4.5)
Mclaren 0 (0) 6 (3.4)
United Healthcare 0 (0) 5 (2.8)
Other 2 (8) 16 (9)
Provider subspecialty,
n (%)
General neurology 0 (0) 61 (34.5)
Resident 22 (88) 37 (20.9)
Neuromuscular 0 (0) 39 (22)
Fellows 0 (0) 31 (17.5)
Attending
neurologist
3 (12) 9 (5.1)
Nurse practioner 0 (0) 0 (0)








13 (52) 97 (54.8)
Gabapentin 4 (16) 40 (22.6)
Nortriptyline 5 (20) 27 (15.3)
Pregabalin 2 (8) 15 (8.5)
Duloxetine 1 (4) 15 (8.5)
Amitriptyline 0 (0) 10 (5.7)
Venlafaxine 1 (4) 3 (1.7)
Doxepin 0 (0) 2 (1.1)
Opioids 0 (0) 11 (6.2)
Oxycodone 0 (0) 6 (3.4)
Methadone 0 (0) 3 (1.7)
Morphine 0 (0) 3 (1.7)
Buprenorphine, naloxone 0 (0) 2 (1.1)
Fentanyl 0 (0) 1 (0.6)
Hydrocodone 0 (0) 1 (0.6)
Other potential pain medications
Tramadol 0 (0) 14 (7.9)
Topiramate 1 (4) 7 (4)
Zonisamide 0 (0) 8 (4.5)
Carbamazepine 0 (0) 7 (4)
Lamotrigine 0 (0) 7 (4)
Baclofen 2 (8) 4 (2.3)
Levetiracetam 0 (0) 5 (2.8)
Lidocaine 1 (0) 4 (2.3)
Other 4 (16) 13 (7.3)
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recommendation when responses were required.11 Therefore, it is
unclear whether higher use would improve prescribing patterns. Rather
than a mandatory response CDSS, other strategies could be employed
to incentivize providers to use the intervention through financial
bonuses or other means.14 Furthermore, the intervention may have led
to alert fatigue.15 One potential solution is to focus future interventions
on patients that self-report pain and/or are not taking current
guideline-recommended medications. Finally, embedding a predictive
tool into the BPA to help determine which patients would most benefit
from a specific medication could increase the perceived utility of the
CDSS.16,17 Future CDSS interventions should (1) implement a more
intensive implementation strategy to increase provider participation or
(2) plan for low use rates when determining sample size and follow-up
length. The second study shortcoming was that the distribution of
patients in the two arms of our trial was asymmetric despite stratifica-
tion by provider type. To mitigate this issue, future studies could
increase the number of physicians randomized through a multicenter
study or stratify physicians on the basis of previous frequencies of out-
patient neuropathy visits.
Changing physician behavior is difficult, even when implementing
a CDSS that follows the typical workflow for ordering medications.
One possible solution would be to target physicians with less experi-
ence, such as residents. Unfortunately, previous meta-analyses have
found no association between physician experience and CDSS inter-
vention effectiveness.12,18,19 Our finding that residents have higher
rates of CDSS use warrants further study.
Study limitations include the small sample and the asymmetric
distribution of physicians in each group. Given the small sample, we
were unable to account for the nested, networked nature of trainees
being supervised by different attending neurologists. Whether our
results are generalizable to other provider specialties is unclear. We
did not have baseline data from the time period immediately prior to
the intervention; therefore, we do not know whether the two groups
were balanced at baseline in terms of medication use. This study was
unable to address whether the intervention would be successful with
mandatory BPAs.
Our proposed CDSS was unsuccessful, both in its use and in alter-
ing prescribing patterns of guideline-recommended medications. Per-
forming RCTs to assess the effectiveness of CDSS interventions is
essential. Lack of rigorous testing may lead to ineffective CDSS that
add unnecessary work to physicians. Our negative trial allowed us to
delete this BPA and lessen the burden on neurologists at the Univer-
sity of Michigan.
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Abstract
Introduction: Electrical impedance myography (EIM) has been proposed as a noninva-
sive biomarker of muscle composition in facioscapulohumeral muscular dystrophy
(FSHD). Here we determine the associations of EIM variables with muscle structure
measured by MRI.
Methods: We evaluated 20 patients with FSHD at two centers, comparing EIM mea-
surements (resistance, reactance, and phase at 50, 100, and 211 kHZ) recorded from
bilateral vastus lateralis, tibialis anterior, and medial gastrocnemius muscles to MRI
skin and subcutaneous fat thickness, MRI T1-based muscle severity score (T1 muscle
score), and MRI quantitative intramuscular Dixon fat fraction (FF).
Abbreviations: 6MWT, 6-Minute Walk Test; CSS, clinical severity score; DMD, Duchenne muscular dystrophy; EIM, electrical impedance myography; FF, MRI quantitative intramuscular Dixon
fat fraction; FOV, field of view; FSHD, facioscapulohumeral muscular dystrophy; KUMC, University of Kansas Medical Center; MG, medial gastrocnemius muscle; SC, MRI skin and subcutaneous
fat thickness; STIR, MRI short τ-inversion recovery; T1 muscle score, MRI T1-based muscle severity score; TA, tibialis anterior muscle; TE, time to echo; TR, repetition time; URMC, University of
Rochester Medical Center; VL, vastus lateralis muscle.
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